News from exact sciences corp A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 03, 2020, 06:00 ET Exact Sciences to participate in August investor conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to...


Jul 30, 2020, 16:05 ET Exact Sciences Announces Second Quarter 2020 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $268.9 million for the second quarter ended June 30, 2020,...


Jul 08, 2020, 06:00 ET Exact Sciences schedules annual meeting, second quarter 2020 earnings call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020...


Jun 16, 2020, 08:00 ET Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

Exact Sciences Corp. (NASDAQ: EXAS) today announced the publication of results highlighting the performance of the Oncotype DX Genomic Prostate...


May 29, 2020, 08:00 ET Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

Exact Sciences Corp. (NASDAQ: EXAS) today announced it is presenting new data at the 2020 American Society of Clinical Oncology (ASCO20) Virtual...


May 26, 2020, 06:00 ET Exact Sciences to participate in June investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to...


May 14, 2020, 06:00 ET New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

Exact Sciences Corp. (NASDAQ: EXAS) today announced results from a prospective clinical survey of the Oncotype DX Breast Recurrence Score® test,...


May 06, 2020, 16:05 ET Exact Sciences Announces First Quarter 2020 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $347.8 million for the first quarter ended Mar. 31, 2020,...


May 05, 2020, 10:30 ET New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

New research from Exact Sciences Corp. (NASDAQ: EXAS) uses real-world-adjusted adherence rates in a colorectal cancer microsimulation, the Colorectal ...


May 04, 2020, 06:00 ET Exact Sciences to participate in May investor conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited...


Apr 08, 2020, 06:00 ET Exact Sciences schedules first-quarter 2020 earnings call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2020 financial results after the close of the ...


Apr 02, 2020, 06:00 ET Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth

Exact Sciences Corp. (NASDAQ: EXAS) today announced it would be devoting significant patient education resources toward the ability to request...


Mar 19, 2020, 06:00 ET Exact Sciences Takes Action during COVID-19 Pandemic

Exact Sciences Corp. (NASDAQ: EXAS) today provided an update on the actions it is taking to support patients, employees, and public health...


Mar 11, 2020, 10:00 ET Fight Colorectal Cancer Receives Grant from Exact Sciences to Launch Program Aimed at Reducing Patient Barriers to Colorectal Cancer Screening

Fight Colorectal Cancer (Fight CRC) announced today the launch of the Catalyst State-by-State Advocacy Program, with the help of an unrestricted...


Mar 03, 2020, 16:05 ET Exact Sciences Extends Leadership In Advanced Cancer Diagnostics With Acquisitions Of Paradigm And Viomics

(NASDAQ: EXAS) – Exact Sciences Corp. today announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two...


Feb 26, 2020, 06:00 ET Exact Sciences to participate in March investor conferences

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conferences and invited...


Feb 24, 2020, 22:39 ET Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2028

Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced that it has priced its underwritten public offering of 0.3750% convertible...


Feb 24, 2020, 16:01 ET Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028

Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $850 million aggregate principal amount...


Feb 11, 2020, 16:05 ET Exact Sciences Announces Fourth-Quarter 2019 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $295.6 million for the fourth quarter ended Dec. 31, 2019...


Jan 27, 2020, 06:00 ET Exact Sciences schedules fourth-quarter, full-year 2019 earnings call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2019 financial results after...


Jan 12, 2020, 19:00 ET Exact Sciences Announces Preliminary Fourth Quarter 2019 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $294 million and $296 million for the fourth...


Jan 02, 2020, 06:00 ET Exact Sciences to participate in J.P. Morgan Healthcare Conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited...


Dec 12, 2019, 06:00 ET New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio...


Dec 04, 2019, 16:30 ET Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors

Exact Sciences Corp. (NASDAQ: EXAS) today announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division...


Nov 26, 2019, 06:00 ET Exact Sciences to participate in December investor conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be participating in the following investor conference. Evercore ISI...